Daiichi Life Insurance Co. Ltd. Buys Shares of 7,091 Illumina, Inc. $ILMN

Posted by George Bondi on Aug 25th, 2026

Daiichi Life Insurance Co. Ltd. purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 7,091 shares of the life sciences company’s stock, valued at approximately $1,247,000.

Several other institutional investors have also modified their holdings of ILMN. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina in the 2nd quarter worth approximately $32,000. Rakuten Securities Inc. purchased a new position in Illumina in the 2nd quarter valued at approximately $33,000. Elyxium Wealth LLC acquired a new position in Illumina during the fourth quarter worth $25,000. TD Waterhouse Canada Inc. acquired a new position in Illumina during the fourth quarter worth $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina during the fourth quarter worth $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $223.22 on Tuesday. The stock’s 50 day moving average price is $189.13 and its 200 day moving average price is $153.14. The firm has a market cap of $33.71 billion, a P/E ratio of 41.65, a PEG ratio of 3.09 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $223.97.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the business posted $1.19 earnings per share. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ILMN shares. Stifel Nicolaus upped their target price on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Barclays boosted their price objective on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, TD Cowen raised their target price on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $188.40.

View Our Latest Report on Illumina

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares in the company, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,095,958 shares of company stock worth $401,720,974 in the last ninety days. 2.90% of the stock is currently owned by insiders.

Illumina Company Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.